A Major Milestone in AVIM Therapy Patents
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has achieved a significant milestone by expanding its global intellectual property estate to include 137 issued patents for its innovative AVIM therapy aimed at treating hypertension and heart failure. This advancement marks a fundamental step in the company's mission to provide cutting-edge solutions to patients suffering from these life-threatening conditions.
Expansion of Patent Portfolio
Over the past year, Orchestra BioMed has successfully secured ten new patents focusing specifically on hypertension treatment. This brings their total for hypertension-related patents to 120 across the globe. Furthermore, the company has fortified its patent estate for treating heart failure, now encompassing an impressive additional 17 global patents. This expansion underscores the extensive reach of their intellectual property portfolio, which includes a total of 46 issued U.S. patents and 91 patents in other international markets.
The Importance of AVIM Therapy
Designed to particularly benefit patients struggling with uncontrolled hypertension, AVIM therapy is under rigorous evaluation in the BACKBEAT global pivotal study. This program is a collaboration with Medtronic, focusing on individuals who have or require a pacemaker. These patients are particularly susceptible to severe cardiovascular events, making this therapy an appealing option for improving their quality of life.
Advancements in Regulatory Recognition
Recently, the U.S. Food and Drug Administration (FDA) recognized the potential of AVIM therapy by granting it Breakthrough Device Designation. This designation is a testament to the therapy's possible effectiveness for patients at risk of heart failure and increases the urgency for its development and deployment. The criteria set by the FDA serve to expedite the review processes for devices that might significantly improve treatment options for patients.
The Global Patent Landscape
The portfolio of patents held by Orchestra BioMed includes critical protections in key markets including the United States, Europe, Japan, and China. Such strong international patent coverage not only safeguards their innovative technology but also positions the company favorably in the global healthcare market.
Collaborative Strategies in Development
Orchestra BioMed operates under a partnership-enabled business model, forging strategic alliances with leading medical device companies to facilitate the commercialization of its products. Their flagship product, AVIM therapy, aims to address hypertension, which is a leading global risk factor for death.
Moreover, the company is also developing the Virtue Sirolimus AngioInfusion™ Balloon (SAB) targeting the treatment of atherosclerotic artery disease, further showcasing their commitment to addressing prevalent health issues that contribute to mortality worldwide.
Commitment to Addressing Hypertension and Heart Failure
The growing epidemic of hypertension and related cardiovascular diseases, which affects millions globally, necessitates innovative solutions like AVIM therapy. Orchestra BioMed's ongoing research and patent expansion efforts reflect their strategic commitment to improving patient outcomes and supporting healthcare providers in their efforts to combat these prevalent diseases.
Frequently Asked Questions
What is AVIM therapy?
AVIM therapy is a new investigational treatment aimed at significantly lowering blood pressure and is compatible with standard dual-chamber pacemakers.
How many patents has Orchestra BioMed secured for AVIM therapy?
Orchestra BioMed has secured a total of 137 patents worldwide for their AVIM therapy, which covers treatment for hypertension and heart failure.
What recognition has AVIM therapy received from the FDA?
AVIM therapy has been granted Breakthrough Device Designation by the FDA, highlighting its potential effectiveness in treating uncontrolled hypertension.
In which markets does Orchestra BioMed hold patent protections?
The company holds patent protections in key markets, including the United States, Europe, Japan, and China.
What is the significance of the BACKBEAT study?
The BACKBEAT study is a pivotal trial evaluating the safety and efficacy of AVIM therapy in patients with uncontrolled hypertension requiring pacemakers, demonstrating its broader clinical impact.
